GnRH Agonist and Intrauterine Insemination

Instituto Valenciano de Infertilidad, IVI VALENCIA

Overview

The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

SINGLE

Conditions

Intrauterine Insemination

Interventions

TryptorelinDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 38 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women \< 38 years old * Bilateral tubal patency confirmed by hysterosonography * Normal ultrasound scan of uterus and ovaries * Normal day 3 basal hormones * Motile sperm count after capacitation ≥ 3 mill/ml Exclusion Criteria: * Endometriosis * Polycystic ovary syndrome * Uterine disease (polyps, myomas and müllerian diseases)

Locations (1)

Instituto Valenciano de Infertilidad Spain

Valencia, Valencia, Spain

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.